Epilepsy
Valeant Pharmaceuticals Completes Enrollment of Second Pivotal Phase 3 Trial for Epilepsy Drug Retigabine
Published in Medical Letter on the CDC and FDA, December 16th, 2007
Valeant Pharmaceuticals International (NYSE:VRX) announced that it has achieved full enrollment in RESTORE2, its second pivotal Phase 3 study of retigabine in the treatment of epilepsy. Retigabine is a first-in-class neuronal potassium channel opener demonstrated to be effective in a recently published Phase 2b epilepsy study. The RESTORE1 and RESTORE2 trials (Retigabine Efficacy and Safety Trials for Partial Onset Epilepsy) are designed to evaluate the efficacy and safety of retigabine as an adjunctive therapy in patients with refractory partial-onset seizures who are receiving one, two or three concomitant antiepileptic drugs (AEDs). RESTORE2 is investigating retigabine at 600 and 900...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Cancer
Statement by MITA Vice President Andrew Whitman on the Benefits of CT Scans Relative to Radiation Dose Risks - Diabetes
Treating Depression Prolongs Life for Older People with Diabetes - Psychiatry
Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression - Women's Health
Data on women's health discussed by researchers at University of Pittsburgh - Kidneys
New kidneys in children research has been reported by scientists at University of North Carolina - Kidneys
Reports from University of North Carolina highlight recent research in kidneys in children - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
